What is Miostat and how is it used?
Miostat belongs to a class of drugs called Miotics, Direct-Acting; Antiglaucoma, Miotics.
What are the possible side effects of Miostat?
Miostat may cause serious side effects including:
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- new or sudden vision problems,
- seeing “floaters” in your vision, and
- urination problems
Get medical help right away, if you have any of the symptoms listed above.
The most common side effects of Miostat include:
- blurred vision,
- flushing (warmth, redness, or tingly feeling),
- stomach pain,
- headache, and
- a tight feeling in your bladder
Tell the doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Miostat. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
MIOSTAT® (carbachol intraocular solution, USP) is a sterile balanced salt solution of carbachol for intraocular injection. The active ingredient is represented by the chemical structure:
Established name: Carbachol
Chemical name: Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,Ntrimethyl-, chloride.
Molecular Formula: C6H15CIN2O2
Molecular Weight: 182.65
Each mL contains: Active: carbachol 0.01%.
Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dehydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dehydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and Water for Injection. pH range is 6.5-7.5.
Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery.
DOSAGE AND ADMINISTRATION
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
In a 2.0 mL glass vial with a 1.5 mL fill, grey butyl stopper and aluminum seal packaged twelve to a carton.
Store at 15° - 30°C (59° - 86°F).
Distributed by: Alcon Laboratories , Inc., Fort Worth, Texas 76134 USA. Revised: Mar 2016
Systemic: Side effects such as flushing, sweating, epigastric distress, abdominal cramps, tightness in
urinary bladder, and headache have been reported with topical or systemic application of carbachol.
The following additional reactions have been identified during post-approval use of MIOSTAT (carbachol intraocular solution, USP) in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to MIOSTAT, or a combination of these factors, include: corneal edema, drug effect prolonged (miosis), eye inflammation, eye pain, intraocular pressure increased, ocular hyperemia, vision blurred, visual impairment, and vomiting.
No information provided.
For single-dose intraocular use only. Discard unused portion. Intraocular carbachol 0.01% should be used with caution in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. spasm, urinary tract obstruction and Parkinson's disease.
The vial stopper contains natural rubber (latex) which may cause severe allergic reactions.
Use only if the container is undamaged.
Studies in animals to evaluate the carcinogenic potential have not been conducted.
Category C. There are no adequate and well-controlled studies in pregnant women. MIOSTAT® (carbachol intraocular solution, USP) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known if this medication is excreted in breast milk. Exercise caution when administering to a nursing woman.
Safety and efficacy in pediatric patients have not been established.
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Drugs and Treatment Resources
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors